# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BTIG analyst Justin Zelin initiates coverage on TScan Therapeutics (NASDAQ:TCRX) with a Buy rating and announces Price Targe...
HC Wainwright & Co. analyst Andrew Fein reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $15 price t...
Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $11 price target.
Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform and maintains $10 price tar...